Decreased Serum Levels of IL-27and IL-35 in Patients with Graves Disease

Overview

Journal Arch Endocrinol Metab

Specialty Endocrinology

Date 2021 May 25

PMID 34033291

Citations 9

Authors

Malek-Hosseini Saeed

Kalantar Kurosh

Amirghofran Zahra

Dabbaghmanesh Mohamad Hossein

Rostamzadeh Davood

Mohammad Reza Ataollahi

Affiliations

Soon will be listed here.

Abstract

Objective: Graves' disease (GD) is an autoimmune disease causing the overproduction of the thyroid hormone from thyroid gland. This disease is mainly the result of the production of antibodies against TSH receptors. Cytokines play an important role in orchestrating the pathophysiology in autoimmune thyroid disease. The regulatory role of IL-12 on TH1 cells has been proven. IL-27 and IL-35, members of IL-12 cytokine family, are two cytokines that have been newly discovered. IL-35 has been identified as a novel immunosuppressive and anti-inflammatory cytokine while IL-27 has both inflammatory and anti-inflammatory functions. The objective of the current study was to examine the changes in the serum level of the foregoing cytokines in GD patients in comparison to healthy controls.

Methods: In this study, serum levels of IL-27 and IL-35 were determined by an ELISA method; anti TPO and anti Tg were measured by an RIA method in 40 new cases of Graves's disease. The findings were compared with 40 healthy controls.

Results: The results showed a significant difference between IL-27 and IL-35 regarding their serum levels with P values of 0.0001 and 0.024, respectively; anti TPO and anti Tg levels of the cases were also significantly different from controls (p < 0.001).

Conclusion: The reduction in the serum levels of IL-27 and IL-35 in GD patients compared to normal subjects suggests the possible anti-inflammatory role of these cytokines in GD.

Citing Articles

Elucidating the role of T-Reg related cytokines: serum transforming growth factor beta and interleukin-35 in alopecia areata.

Yuksek T, Gonul M, Kartal S, Gungor E, Hatil S Arch Dermatol Res. 2024; 316(6):205.

PMID: 38787409 DOI: 10.1007/s00403-024-02901-9.

Follicular Thyroid Adenoma and Follicular Thyroid Carcinoma-A Common or Distinct Background? Loss of Heterozygosity in Comprehensive Microarray Study.

Borowczyk M, Dobosz P, Szczepanek-Parulska E, Budny B, Debicki S, Filipowicz D Cancers (Basel). 2023; 15(3).

PMID: 36765597 PMC: 9913827. DOI: 10.3390/cancers15030638.

Effect of IL-27, Teriflunomide and Retinoic Acid and Their Combinations on CD4 T Regulatory T Cells-An In Vitro Study.

Maslanka T Molecules. 2022; 27(23).

PMID: 36500570 PMC: 9739213. DOI: 10.3390/molecules27238471.

Reduced circulating interleukin 35 is associated with enhanced peripheral T cell function in primary biliary cholangitis.

Liu S, Zhang Q, Zhang M, Zhong X, Wang W, Wang L Biomol Biomed. 2022; 23(2):248-258.

PMID: 36314719 PMC: 10113946. DOI: 10.17305/bjbms.2022.8147.

Decreased serum interleukin-41/Metrnl levels in patients with Graves' disease.

Gong L, Huang G, Weng L, Xu J, Li Y, Cui W J Clin Lab Anal. 2022; 36(10):e24676.

PMID: 36036749 PMC: 9550969. DOI: 10.1002/jcla.24676.

References

Hunter C, Kastelein R . Interleukin-27: balancing protective and pathological immunity. Immunity. 2012; 37(6):960-9. PMC: 3531794. DOI: 10.1016/j.immuni.2012.11.003. View

Owaki T, Asakawa M, Fukai F, Mizuguchi J, Yoshimoto T . IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J Immunol. 2006; 177(11):7579-87. DOI: 10.4049/jimmunol.177.11.7579. View

Gianoukakis A, Jennings T, King C, Sheehan C, Hoa N, Heldin P . Hyaluronan accumulation in thyroid tissue: evidence for contributions from epithelial cells and fibroblasts. Endocrinology. 2006; 148(1):54-62. DOI: 10.1210/en.2006-0736. View

Lv M, Shen J, Li Z, Zhao D, Chen Z, Wan H . [Role of Treg/Th17 cells and related cytokines in Graves' ophthalmopathy]. Nan Fang Yi Ke Da Xue Xue Bao. 2014; 34(12):1809-13. View

Lai X, Wang H, Cao J, Li Y, Dai Y, Xiang Y . Circulating IL-27 Is Elevated in Rheumatoid Arthritis Patients. Molecules. 2016; 21(11). PMC: 6273926. DOI: 10.3390/molecules21111565. View

Singh K, Kadesjo E, Lindroos J, Hjort M, Lundberg M, Espes D . Interleukin-35 administration counteracts established murine type 1 diabetes--possible involvement of regulatory T cells. Sci Rep. 2015; 5:12633. PMC: 4519737. DOI: 10.1038/srep12633. View

Alpdogan O, van den Brink M . Immune tolerance and transplantation. Semin Oncol. 2012; 39(6):629-42. PMC: 3514882. DOI: 10.1053/j.seminoncol.2012.10.001. View

Frohlich E, Wahl R . Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases. Front Immunol. 2017; 8:521. PMC: 5422478. DOI: 10.3389/fimmu.2017.00521. View

Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N . IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol. 2010; 41(1):47-59. DOI: 10.1002/eji.201040804. View

10.

Kamiya S, Owaki T, Morishima N, Fukai F, Mizuguchi J, Yoshimoto T . An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol. 2004; 173(6):3871-7. DOI: 10.4049/jimmunol.173.6.3871. View

11.

Larousserie F, Charlot P, Bardel E, Froger J, Kastelein R, Devergne O . Differential effects of IL-27 on human B cell subsets. J Immunol. 2006; 176(10):5890-7. DOI: 10.4049/jimmunol.176.10.5890. View

12.

Jankowski M, Kopinski P, Goc A . Interleukin-27: biological properties and clinical application. Arch Immunol Ther Exp (Warsz). 2010; 58(6):417-25. DOI: 10.1007/s00005-010-0098-6. View

13.

Choi J, Leung P, Bowlus C, Gershwin M . IL-35 and Autoimmunity: a Comprehensive Perspective. Clin Rev Allergy Immunol. 2015; 49(3):327-32. DOI: 10.1007/s12016-015-8468-9. View

14.

Gianoukakis A, Khadavi N, Smith T . Cytokines, Graves' disease, and thyroid-associated ophthalmopathy. Thyroid. 2008; 18(9):953-8. PMC: 2879490. DOI: 10.1089/thy.2007.0405. View

15.

Yoshida H, Miyazaki Y, Yoshiyuki M . Regulation of immune responses by interleukin-27. Immunol Rev. 2009; 226:234-47. DOI: 10.1111/j.1600-065X.2008.00710.x. View

16.

Gee K, Guzzo C, Che Mat N, Ma W, Kumar A . The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009; 8(1):40-52. DOI: 10.2174/187152809787582507. View

17.

Collison L, Chaturvedi V, Henderson A, Giacomin P, Guy C, Bankoti J . IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010; 11(12):1093-101. PMC: 3008395. DOI: 10.1038/ni.1952. View

18.

Shen J, Li Z, Li W, Ge Y, Xie M, Lv M . Th1, Th2, and Th17 Cytokine Involvement in Thyroid Associated Ophthalmopathy. Dis Markers. 2015; 2015:609593. PMC: 4451372. DOI: 10.1155/2015/609593. View

19.

Moudgil K, Choubey D . Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res. 2011; 31(10):695-703. PMC: 3189547. DOI: 10.1089/jir.2011.0065. View

20.

Weetman A, Ajjan R, Watson P . Cytokines and Graves' disease. Baillieres Clin Endocrinol Metab. 1998; 11(3):481-97. DOI: 10.1016/s0950-351x(97)80708-2. View